Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01584869
Other study ID # 23042012
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received April 23, 2012
Last updated January 28, 2015
Start date December 2011
Est. completion date March 2014

Study information

Verified date January 2015
Source Technische Universität München
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

Primary objective: Evaluation of capsule endoscopy in the emergency setting of severe GI-Bleeding.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

patients with signs of severe GI-bleeding (with melena or dark bloody stool) and hemodynamic instability (defined as (pre)collapse or MAP < 80 mmHg or HR > 110) and/or drop of hemoglobin > 2g/dl/d and/or need of transfusion of minimum of 2 packed red cells

Exclusion Criteria:

missing consent form, pregnancy, origin of bleeding found in upper GI-endoscopy (e.g. blood in the stomach, ulcer, varices with signs of bleeding, mallory-weiss-tear, Angiodysplasia (with signs of bleeding), refluxesophagitis LA C or D) fresh bloody stool, known stenosis of the bowel, known site of bleeding, known inflammatory bowel disease

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
capsule endoscopy


Locations

Country Name City State
Germany Klinikum rechts der Isar München Bavaria

Sponsors (1)

Lead Sponsor Collaborator
Technische Universität München

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary the influence of capsule endoscopy on guidance of further diagnostic or therapeutic procedures. after complete recruitment No
Secondary frequency of mid-GI-bleeding in all patients No
Secondary diagnostic yield after complete recruitment No